Leukemia & Lymphoma Society Launches Navigating Cancer’s Network of Support

Leukemia & Lymphoma Society Launches Navigating Cancer’s Network of Support
0
(0)

The Leukemia and Lymphoma Society (LLS) aims to leverage education about blood cancers, including leukemia, lymphoma and myeloma, through a new partnership with Navigating Cancer, a patient relationship management company.

Navigating Cancer’s patient education service includes content from sources such as the National Cancer Institute (NCI). With the support of LLS, the network will now offer its community access to a series of free resources and services for blood cancer patients.

The platform will link to the LLS website so that patients can connect with information specialists, social workers, and nurses at LLS who work personally with blood cancer patients.

The platform will connect patients with personalized information to fit a patient’s specific diagnosis, such as:

  • A clinical trial support center – a service designed to assist patients in finding the right clinical trial for them;
  • Financial support – designed to offer assistance with treatment costs, transportation costs, and daily expenses;
  • An LLS community – a support network for blood cancer patients and caregivers, so they can get support and answers to questions.
  • The Patti Robinson Kaufmann first connection program – a program to help patients and caregivers cope with blood cancer in a peer-to-peer way, with patients being matched with trained volunteers who have also experienced blood cancer firsthand.
  • Co-pay assistance – a service for eligible patients to help pay for prescription drug co-pays and health insurance premiums.
  • Local support groups – Where patients and their families have a place to go where they can share information and talk about their feelings in a welcoming and caring environment close to where they live.

“Our company has always been committed to making the patient the center of their care, and personalized resources are an important component. This new content will give our providers and patients one more tool to help them manage their care,” Gena Cook, CEO of Navigating Cancer, said in a press release.

“Through Navigating Cancer’s portal, our ability to reach out to blood cancer patients and offer them our suite of patient services, including educational materials, talking one-on-one to information specialists, as well as potential financial assistance resources, will assist patients in gaining comfort in the care their providers are managing,” added Gwen Nichols, chief medical officer of the LLS.

Navigating Cancer was founded in 2008 as the result of two healthcare and tech veterans collaborating to fill a gap in oncology care: a better patient experience. Today, Navigating Cancer supports over one million patients and thousands of cancer care providers nationwide to lower costs, improve patient satisfaction, and fight for better outcomes.

LLS blood cancer information specialists are available from 9 a.m. to 9 p.m. Eastern time Monday to Friday at 800-955-4572, by live chat or by email via LLS.org. The service is offered to patients or caregivers in 170 languages.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • ATG-019 Phase 1 trial
  • ME-401, FDA fast track
  • Tafasitamab combo, lymphoma
  • blood biomarkers

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?